SAN CARLOS, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company
developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the first
patient was dosed in its C-145-04 Phase 2 trial of LN-145 for the treatment of patients with recurrent, metastatic or persistent
cervical carcinoma.
“This marks an important milestone for Iovance, as patient dosing is now ongoing in all three of our internal Phase 2 trials. We
initiated this study based on encouraging data generated by the National Cancer Institute (NCI) showing responses in three of the
nine cervical cancer patients treated with TIL therapy. This patient population had received standard of care treatment including
prior chemotherapy or chemoradiotherapy. Two patients from this study continued to have a complete response at 46 months and 54
months of follow up. The C-145-04 trial will investigate the effect of Iovance’s TIL therapy in cervical cancer patients. We look
forward to progressing the study with the intent to report some initial data in 2018,” said Dr. Maria Fardis, PhD, MBA, Chief
Executive Officer of Iovance Biotherapeutics.
LN-145 is an adoptive cell transfer (ACT) therapy that utilizes an autologous TIL manufacturing process as originally developed
by the NCI. C-145-04 is a Phase 2, multicenter, single-arm, open-label interventional study that will enroll up to 47 patients and
will assess the safety and efficacy of LN-145 for the treatment of patients with recurrent, metastatic, or persistent cervical
carcinoma. The cell transfer therapy used in this study involves patients receiving a non-myeloablative (NMA) lymphocyte depleting
preparative regimen, followed by infusion of autologous TIL and the administration of a regimen of up to six doses of IL-2.
Additional information on this study is available at www.clinicaltrials.gov using the identifier number NCT03108495.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products
for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating
lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic
squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information,
please visit http://www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking
statements. In particular, the Company’s statements regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the
success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation and completion of the trials; the timing of and our ability to obtain and
maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product
candidates; the strength of Company’s product pipeline; the successful implementation of the Company’s research and development
programs and collaborations; the success of the Company’s license or development agreements; the acceptance by the market of the
Company’s product candidates, if approved; and other factors, including general economic conditions and regulatory developments,
not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially
different from those expressed in or implied by such statements. A further list and description of the Company’s risks,
uncertainties and other factors can be found in the Company’s most recent Annual Report on Form 10-K and the Company's subsequent
filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or www.iovance.com. The forward-looking statements are made only as of the date of this press
release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or
circumstance.
Investor Relations Contact: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 sarah@sternir.com Media Relations Contact: Evan Smith/Kotaro Yoshida FTI Consulting 212-850-5622/212-850-5690 evan.smith@fticonsulting.com kotaro.yoshida@fticonsulting.com
